The overall goal of the Clinical Oncology Research Career Development Program is to support the intent of the Paul Calabresi Award for Clinical Oncology (K12). The Program fosters interdisciplinary training in clinical and translational oncology therapeutic research for physicians and doctoral trained nurses with a clinical training background in one of a number of oncology disciplines, including medical, surgical, dermatologic, pediatric, radiation, and nursing oncology. By designing a K12 program that brings together these broad disciplines, the Paul Calabresi Scholars themselves form a multidisciplinary group whose collaborations and interactions augment the overall training efforts under the K12 program. Firm core requirements include completion of required and elective course work for a Masters of Science degree. In addition, basic research components are required as part of the extended training program. These efforts will result in highly qualified Paul Calabresi scholars capable of independent research in clinical oncology and therapeutics based in hypothesis testing of important translational questions in the field. The Program brings together a strong Advisory Committee committed and experienced in the area of clinical translational therapeutics research in oncology and provides scholars with an outstanding environment to pursue career development. Past trainees have all emerged as academic physicians developing independent clinical research programs often with external funding and all with active investigator-initiated clinical trial efforts.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Physician Scientist Award (Program) (PSA) (K12)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Lei, Ming
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Case Western Reserve University
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Okoye, Christian C; Bucher, Jessica; Tatsuoka, Curtis et al. (2017) Cardiovascular risk and prevention in patients with head and neck cancer treated with radiotherapy. Head Neck 39:527-532
Caimi, Paolo F; Cooper, Brenda W; William, Basem M et al. (2017) Phase I clinical trial of the base excision repair inhibitor methoxyamine in combination with fludarabine for patients with advanced hematologic malignancies. Oncotarget 8:79864-79875
Gutierrez, Daniel; Arbesman, Joshua (2016) Circadian Dysrhythmias, Physiological Aberrations, and the Link to Skin Cancer. Int J Mol Sci 17:
Eads, Jennifer R; Beumer, Jan H; Negrea, Lavinia et al. (2016) A pharmacokinetic analysis of cisplatin and 5-fluorouracil in a patient with esophageal cancer on peritoneal dialysis. Cancer Chemother Pharmacol 77:333-8
Malek, Ehsan; de Lima, Marcos; Letterio, John J et al. (2016) Myeloid-derived suppressor cells: The green light for myeloma immune escape. Blood Rev 30:341-8
de Blank, Peter M K; Fisher, Michael J; Lu, Lu et al. (2016) Impact of vision loss among survivors of childhood central nervous system astroglial tumors. Cancer 122:730-9
Gollamudi, Jahnavi; Parvani, Jenny G; Schiemann, William P et al. (2016) Neoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumab. Cancer Manag Res 8:21-31
Telli, Melinda L; Jensen, Kristin C; Vinayak, Shaveta et al. (2015) Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105. J Clin Oncol 33:1895-901
Peiris, Pubudu M; Abramowski, Aaron; Mcginnity, James et al. (2015) Treatment of Invasive Brain Tumors Using a Chain-like Nanoparticle. Cancer Res 75:1356-65
Goebel, Teresa E; Schiltz, Nicholas K; Woodside, Kenneth J et al. (2015) Neoplastic and non-neoplastic complications of solid organ transplantation in patients with preexisting monoclonal gammopathy of undetermined significance. Clin Transplant 29:851-7

Showing the most recent 10 out of 58 publications